Collegium Pays Grünenthal $17 Million To End Nucynta License And Royalties, Settling Patent Suit
The settlement also hands Collegium certain Nucynta-related patents, and Grünenthal has moved to dismiss its infringement suit.
Collegium Pharmaceutical paid Grünenthal $17,000,000 to settle every dispute between them and end the Nucynta license, according to an 8-K filed Monday. The agreement was signed Thursday, and no further royalties are due under the license.
What the 8-K says
The filing, under Item 1.02 (termination of a material agreement), says Collegium and Grünenthal signed a settlement agreement on October 15, 2026. It resolves all claims between the parties, including the patent suit Grünenthal filed in February 2026 in federal court in the District of New Jersey.
That suit alleged patent infringement tied to the launch of the authorized generic of Nucynta ER.
The parties agreed to end the Grünenthal license in its entirety. The termination took effect on October 15 after Collegium made the $17,000,000 payment.
The filing says all of Collegium's royalty obligations under the license "have been fully and finally discharged."
Grünenthal also assigned certain patents related to the Nucynta products to Collegium. It filed a motion to dismiss the New Jersey case as well.
What it changes
Collegium assumed the license, originally dated January 13, 2015, through a consent agreement dated January 30, 2020. That came with its 2020 purchase of Nucynta ER and Nucynta IR.
The consent agreement is ended only for the Territory, a term the agreement defines. Otherwise it stays in force on its terms.
For holders, the royalty obligation to Grünenthal is gone in exchange for a one-time $17,000,000 payment. Collegium now also holds patents it did not have before.
Collegium's stock closed at $23.01 in Monday's session, down 0.78%, versus $23.19 in the prior session. The filing was accepted at 4:05 p.m. ET, after that close.
What to watch
The federal court in New Jersey still has to act on Grünenthal's motion to dismiss the suit.
Until the court rules on the motion, the infringement case sits in New Jersey on the docket, even though both sides have settled.